" class="no-js "lang="en-US"> Oncology Archives - Page 2 of 53 - Medtech Alert
Wednesday, September 03, 2025

Sort by:

Date

Top Post

Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study

Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]

SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment

SciTech Development has announced it has closed a $2.73M funding round, led by several prominent […]

Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer

Eureka Therapeutics, a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced […]

FluoGuide Announces Positive Topline Results from Phase IIa Trial of FG001 in Lung Cancer

FluoGuide, a Danish biotech company that pioneers precision cancer surgery, is pleased to announce positive […]

BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

BPGbio, a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced […]

The Combination of ISA101b and Libtayo® Shows Promising Results in Patients Whose Head and Neck Cancer Progressed on Anti-PD1 Therapy

ISA Pharmaceuticals B.V., a clinical-stage biotechnology company developing immunotherapies to treat cancers and serious infectious […]

GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, has announced an equity […]

Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel […]

Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting

Promontory Therapeutics, a clinical-stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data […]

CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more